317 related articles for article (PubMed ID: 20382128)
1. Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma.
Flaherty KT; Puzanov I
Biochem Pharmacol; 2010 Sep; 80(5):638-46. PubMed ID: 20382128
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.
Mulders P
BJU Int; 2009 Dec; 104(11):1585-9. PubMed ID: 20053190
[TBL] [Abstract][Full Text] [Related]
3. Targeted agents for the treatment of advanced renal cell carcinoma.
Stadler WM
Cancer; 2005 Dec; 104(11):2323-33. PubMed ID: 16240452
[TBL] [Abstract][Full Text] [Related]
4. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies.
Costa LJ; Drabkin HA
Oncologist; 2007 Dec; 12(12):1404-15. PubMed ID: 18165617
[TBL] [Abstract][Full Text] [Related]
5. Molecularly targeted agents for renal cell carcinoma: the next generation.
Cowey CL; Hutson TE
Clin Adv Hematol Oncol; 2010 May; 8(5):357-60, 361-4. PubMed ID: 20551895
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
Liu MY; Poellinger L; Walker CL
Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
[TBL] [Abstract][Full Text] [Related]
7. Combination targeted therapy in advanced renal cell carcinoma.
Sosman J; Puzanov I
Cancer; 2009 May; 115(10 Suppl):2368-75. PubMed ID: 19402058
[TBL] [Abstract][Full Text] [Related]
8. Understanding the importance of smart drugs in renal cell carcinoma.
Patard JJ; Rioux-Leclercq N; Fergelot P
Eur Urol; 2006 Apr; 49(4):633-43. PubMed ID: 16481093
[TBL] [Abstract][Full Text] [Related]
9. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
Sosman JA; Puzanov I; Atkins MB
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
[TBL] [Abstract][Full Text] [Related]
10. [mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma].
Ravaud A; Bernhard JC; Gross-Goupil M; Digue L; Ferriere JM
Bull Cancer; 2010; 97():45-51. PubMed ID: 20418203
[TBL] [Abstract][Full Text] [Related]
11. The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma.
Choueiri TK; Bukowski RM; Rini BI
Semin Oncol; 2006 Oct; 33(5):596-606. PubMed ID: 17045089
[TBL] [Abstract][Full Text] [Related]
12. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.
Bellmunt J; Montagut C; Albiol S; Carles J; Maroto P; Orsola A
BJU Int; 2007 Feb; 99(2):274-80. PubMed ID: 17092282
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathways in renal cell carcinoma--rationale for targeted treatment.
Kim WY; Kaelin WG
Semin Oncol; 2006 Oct; 33(5):588-95. PubMed ID: 17045088
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy for renal cell cancer: current perspectives.
van der Veldt AA; Haanen JB; van den Eertwegh AJ; Boven E
Discov Med; 2010 Nov; 10(54):394-405. PubMed ID: 21122471
[TBL] [Abstract][Full Text] [Related]
15. Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma.
Rini BI; Rathmell WK
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):741s-746s. PubMed ID: 17255303
[TBL] [Abstract][Full Text] [Related]
16. Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.
Bukowski RM
Expert Opin Pharmacother; 2010 Oct; 11(14):2351-62. PubMed ID: 20586712
[TBL] [Abstract][Full Text] [Related]
17. The role of vascular endothelial growth factor in kidney and prostate cancer.
Delongchamps NB; Peyromaure M
Can J Urol; 2007 Oct; 14(5):3669-77. PubMed ID: 17949520
[TBL] [Abstract][Full Text] [Related]
18. Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma.
Rini BI; Flaherty K
Urol Oncol; 2008; 26(5):543-9. PubMed ID: 18774471
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy of renal cell cancer.
Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
Curr Opin Investig Drugs; 2008 Jun; 9(6):570-5. PubMed ID: 18516756
[TBL] [Abstract][Full Text] [Related]
20. Management of mTOR inhibitor side effects.
Creel PA
Clin J Oncol Nurs; 2009 Dec; 13 Suppl():19-23. PubMed ID: 19948456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
